首页> The Journal of clinical investigation> Baricitinib restrains the immune dysregulation in patients with severe COVID-19.

Baricitinib restrains the immune dysregulation in patients with severe COVID-19.

导出 OA

翻译打印收藏纠错

第一作者： Vincenzo,Bronte

第一单位： Immunology Section, Department of Medicine.

作者： Vincenzo,Bronte ^[1] ; Stefano,Ugel ^[1] ; Elisa,Tinazzi ^[2] ; Antonio,Vella ^[1] ; Francesco,De Sanctis ^[1] ; Stefania,Canè ^[1] ; Veronica,Batani ^[1] ; Rosalinda,Trovato ^[1] ; Alessandra,Fiore ^[1] ; Varvara,Petrova ^[1] ; Francesca,Hofer ^[1] ; Roza Maria,Barouni ^[1] ; Chiara,Musiu ^[1] ; Simone,Caligola ^[1] ; Laura,Pinton ^[1] ; Lorena,Torroni ^[3] ; Enrico,Polati ^[4] ; Katia,Donadello ^[4] ; Simonetta,Friso ^[2] ; Francesca,Pizzolo ^[2] ; Manuela,Iezzi ^[5] ; Federica,Facciotti ^[6] ; Pier Giuseppe,Pelicci ^[6] ; Daniela,Righetti ^[7] ; Paolo,Bazzoni ^[7] ; Mariaelisa,Rampudda ^[7] ; Andrea,Comel ^[7] ; Walter,Mosaner ^[7] ; Claudio,Lunardi ^[2] ; Oliviero,Olivieri ^[2]

作者单位： Immunology Section, Department of Medicine. ^[1] Internal Medicine Section B, Department of Medicine. ^[2] Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy. ^[3] Intensive Care Unit, Department of Surgery, Dentistry, Maternity and Infant, University and Hospital Trust of Verona, Verona, Italy. ^[4] Center for Advanced Studies and Technology (CAST), University of G. D'Annunzio of Chieti-Pescara, Chieti, Italy. ^[5] Department of Experimental Oncology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy. ^[6] Pederzoli Hospital, Peschiera sul Garda, Italy. ^[7]

关键词 COVID-19 Immunology Innate immunity